Blankenberg Francis G, Kalinyak Judy, Liu Liping, Koike Maya, Cheng Danye, Goris Michael L, Green Allan, Vanderheyden Jean-Luc, Tong David C, Yenari Midori Anne
Division of Pediatric Radiology/Department of Radiology, Stanford University Hospital, 725 Welch Road, Rm #1673, Lucile Packard Children's Hospital, Palo Alto, CA 94305, USA.
Eur J Nucl Med Mol Imaging. 2006 May;33(5):566-74. doi: 10.1007/s00259-005-0046-6. Epub 2006 Feb 14.
The first aim of the study was to determine whether (99m)Tc-HYNIC-annexin V, a marker of cellular stress and apoptosis, can detect ischemic injury in patients with acute stroke. Secondly, we wished to test radiolabeled annexin's ability to monitor therapy in a rodent model of focal ischemic injury.
SPECT imaging of patients was performed between 1 and 2 h after intravenous injection of 30 mCi (1,110 MBq) of tracer. Eight MFL4 (anti-FasL) antibody-treated (400 microg i.p. days 0 and 3) and 21 control adult male Sprague-Dawley rats underwent small animal SPECT imaging with 5-10 mCi (185-370 MBq) of tracer, 1 and 6 days after a 2-h intraluminal thread occlusion of the left middle cerebral artery.
Two patients with acute stroke had regions of multifocal annexin uptake that correlated with sites of restricted diffusion on MRI. Anti-FasL antibody treatment significantly reduced annexin uptake by 92% with a 60% decrease in the number of caspase-8 staining (apoptotic) neurons on day 1. On day 6, treated animals had an 80% reduction in tracer uptake with a 75% decrease in infarct size as compared with controls. Annexin uptake in controls and treated animals (day 6) linearly correlated with infarct size (r (2)=0.603, p=0.0036) and the number of TUNEL-positive (apoptotic) nuclei (r (2)=0.728, p=0.00084).
Annexin imaging shows foci of increased uptake at sites of ischemic injury in patients with acute stroke. Annexin imaging can assess the effects of therapy for ischemic cerebral injury in rats, suggesting its potential as a non-invasive indicator of drug efficacy in future clinical trials.
本研究的首要目的是确定细胞应激和凋亡标志物(99m)Tc-HYNIC-膜联蛋白V能否检测急性中风患者的缺血性损伤。其次,我们希望在局灶性缺血性损伤的啮齿动物模型中测试放射性标记膜联蛋白监测治疗的能力。
在静脉注射30 mCi(1110 MBq)示踪剂后1至2小时对患者进行单光子发射计算机断层扫描(SPECT)成像。8只经MFL4(抗FasL)抗体处理(第0天和第3天腹腔注射400μg)的成年雄性Sprague-Dawley大鼠和21只对照成年雄性Sprague-Dawley大鼠在左大脑中动脉腔内丝线闭塞2小时后1天和6天,接受了5 - 10 mCi(185 - 370 MBq)示踪剂的小动物SPECT成像。
两名急性中风患者有多灶性膜联蛋白摄取区域,与磁共振成像(MRI)上的扩散受限部位相关。抗FasL抗体治疗在第1天显著降低膜联蛋白摄取92%,半胱天冬酶-8染色(凋亡)神经元数量减少60%。在第6天,与对照组相比,治疗组动物的示踪剂摄取减少80%,梗死体积减少75%。对照组和治疗组动物(第6天)的膜联蛋白摄取与梗死体积(r² = 0.603,p = 0.0036)和末端脱氧核苷酸转移酶介导的缺口末端标记(TUNEL)阳性(凋亡)细胞核数量(r² = 0.728,p = 0.00084)呈线性相关。
膜联蛋白成像显示急性中风患者缺血性损伤部位摄取增加的病灶。膜联蛋白成像可评估大鼠缺血性脑损伤的治疗效果,提示其在未来临床试验中作为药物疗效非侵入性指标的潜力。